Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Acumen Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Acumen Pharmaceuticals, Inc.

ABOS

Acumen Pharmaceuticals, Inc.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing sabirnetug, a novel monoclonal antibody targeting soluble amyloid-beta oligomers (AβOs) implicated in early Alzheimer's disease. The company’s immunotherapy aims to slow disease progression by neutralizing AβO toxicity, offering a differentiated approach from existing treatments. Acumen relies on third-party manufacturing and clinical partnerships, targeting patients with mild cognitive impairment or mild dementia due to Alzheimer's.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Acumen Pharmaceuticals, Inc.

1
1
Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals Reports $20.7 Million Net Loss in Q1 2026, Reduces Operating Expenses

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals Reports $121.3 Million Net Loss for 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals Reports $26.5M Net Loss in Q3 2025, Sees Increase in R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals Reports $40.9 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals Reports Increased Net Loss of $28.8 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals Reports $102.3 Million Net Loss for 2024, Driven by Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals Reports Net Loss, Decrease in Cash Reserves, and Increased Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments